Results 31 to 40 of about 531,165 (296)

Tanespimycin as Antitumor Therapy

Clinical Lymphoma Myeloma and Leukemia, 2011
The 90 kDa heat shock protein (HSP90), which facilitates proper folding and stability of numerous signaling molecules involved in growth control, cell survival, and development, has been implicated in malignant processes. Like its parent compound geldanamycin, tanespimycin binds to HSP90 and causes antineoplastic effects in vitro and in vivo.All ...
Dimopoulos, Meletios-Athanassios, Mitsiades, Constantine S, Anderson, Kenneth C, Richardson, Paul G   +3 more
openaire   +5 more sources

Potential of Steroidal Alkaloids in Cancer: Perspective Insight Into Structure–Activity Relationships

Frontiers in Oncology, 2021
Steroidal alkaloids contain both steroidal and alkaloid properties in terms of chemical properties and pharmacological activities. Due to outstanding biological activities such as alkaloids and similar pharmacological effects to other steroids, steroidal
Ying Huang, Gen Li, Chong Hong, Xia Zheng, Haiyang Yu, Yan Zhang   +5 more
doaj   +1 more source

The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents

Frontiers in Pharmacology, 2020
Platinum-based anticancer drugs, including cisplatin, carboplatin, oxaliplatin, nedaplatin, and lobaplatin, are heavily applied in chemotherapy regimens.
Jiabei Zhou, Yu Kang, Lu Chen, Hua Wang, Junqing Liu, S. Zeng, Lushan Yu   +6 more
semanticscholar   +1 more source

Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer

Journal for ImmunoTherapy of Cancer, 2022
Background Agents blocking programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) have been approved for triple-negative breast cancer (TNBC).
Ming Yi, Yuze Wu, Mengke Niu, Shuangli Zhu, Jing Zhang, Yongxiang Yan, P. Zhou, Zhi-tang Dai, Kongming Wu   +8 more
semanticscholar   +1 more source

circFIG 4 drives the carcinogenesis and metastasis of esophagus cancer via the miR‐493‐5p/E2F3 axis

Thoracic Cancer, 2022
Background Esophageal cancer (EC) is a highly malignant tumor of the digestive tract. Circular RNAs (circRNAs) have been verified to play a regulatory role in the occurrence and progression of different cancers, including EC.
Zhen Huang, Chunyue Wang, Xin Zhao
doaj   +1 more source

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.

Cancer Discovery, 2019
Despite recent advances in the use of immunotherapy, only a minority of patients with small cell lung cancer (SCLC) respond to immune checkpoint blockade (ICB).
T. Sen, B. L. Rodriguez, Limo Chen, C. Corte, N. Morikawa, J. Fujimoto, Sandra Cristea, Thuyen N. Nguyen, L. Diao, Lerong Li, Youhong Fan, Yongbing Yang, Jing Wang, B. Glisson, I. Wistuba, J. Sage, J. Heymach, D. Gibbons, L. Byers   +18 more
semanticscholar   +1 more source

Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity.

Cell, 2019
Differentiation of proinflammatory CD4+ conventional T cells (Tconv) is critical for productive antitumor responses yet their elicitation remains poorly understood.
M. Binnewies, Adriana M. Mujal, Joshua L. Pollack, A. Combes, Chun Jimmie Ye, M. Krummel   +5 more
semanticscholar   +1 more source

RNA-Seq-Based TCR Profiling Reveals Persistently Increased Intratumoral Clonality in Responders to Anti-PD-1 Therapy

Frontiers in Oncology, 2020
Substantial effort is being invested in the search for peripheral or intratumoral T cell receptor (TCR) repertoire features that could predict the response to immunotherapy.
Ekaterina A. Zhigalova, Anna I. Izosimova, Diana V. Yuzhakova, Lilia N. Volchkova, Irina A. Shagina, Irina A. Shagina, Maria A. Turchaninova, Maria A. Turchaninova, Maria A. Turchaninova, Ekaterina O. Serebrovskaya, Ekaterina O. Serebrovskaya, Ekaterina O. Serebrovskaya, Elena V. Zagaynova, Dmitriy M. Chudakov, Dmitriy M. Chudakov, Dmitriy M. Chudakov, Dmitriy M. Chudakov, George V. Sharonov, George V. Sharonov, George V. Sharonov   +19 more
doaj   +1 more source

Measuring Intratumoral Heterogeneity of Immune Repertoires

Frontiers in Oncology, 2020
There is considerable clinical and fundamental value in measuring the clonal heterogeneity of T and B cell expansions in tumors and tumor-associated lymphoid structures—along with the associated heterogeneity of the tumor neoantigen landscape—but such ...
Diana Vladimirovna Yuzhakova, Lilia N. Volchkova, Mikhail Valerievich Pogorelyy, Mikhail Valerievich Pogorelyy, Ekaterina O. Serebrovskaya, Ekaterina O. Serebrovskaya, Irina A. Shagina, Irina A. Shagina, Ekaterina A. Bryushkova, Ekaterina A. Bryushkova, Tatiana O. Nakonechnaya, Tatiana O. Nakonechnaya, Tatiana O. Nakonechnaya, Anna V. Izosimova, Daria S. Zavyalova, Maria M. Karabut, Mark Izraelson, Mark Izraelson, Mark Izraelson, Igor V. Samoylenko, Vladimir E. Zagainov, Vladimir E. Zagainov, Dmitriy M. Chudakov, Dmitriy M. Chudakov, Dmitriy M. Chudakov, Dmitriy M. Chudakov, Dmitriy M. Chudakov, Elena V. Zagaynova, George Vladimirovich Sharonov, George Vladimirovich Sharonov, George Vladimirovich Sharonov   +30 more
doaj   +1 more source

A PRSZT Registry Analysis of Prognostic Factors Influencing Survival and Relapse Rates After Second Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT A second allogeneic (allo‐)hematopoietic stem cell transplantation (HSCT2) is a potential curative option for pediatric patients with acute lymphoblastic leukemia (ALL) following relapse after first allogeneic transplantation (HSCT1), but its efficacy is limited by high relapse rates and transplant‐related toxicity in highly pretreated ...
Ava Momm, Imme Haubitz, Rita Beier, Martin Zimmermann, Andrej Lissat, Peter Bader, Matthias Eyrich, Jan‐Henning Klusmann, Matthias Wölfl, Paul‐Gerhardt Schlegel, Verena Wiegering   +10 more
wiley   +1 more source